-
3
-
-
0038102859
-
Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients
-
DOI 10.1016/S1569-1993(02)00141-8, PII S1569199302001418
-
TW Lee, KG Brownlee, SP Conway, M Denton, JM Littlewood Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients J Cyst Fibros 2 2003 29 34 (Pubitemid 36857407)
-
(2003)
Journal of Cystic Fibrosis
, vol.2
, Issue.1
, pp. 29-34
-
-
Lee, T.W.R.1
Brownlee, K.G.2
Conway, S.P.3
Denton, M.4
Littlewood, J.M.5
-
4
-
-
0142105983
-
Pseudomonas acquisition in young patients with cystic fibrosis: Pathophysiology, diagnosis, and management
-
M Rosenfeld, BW Ramsey, RL Gibson Pseudomonas acquisition in young patients with cystic fibrosis: pathophysiology, diagnosis, and management Curr Opin Pulm Med 9 2003 492 497 (Pubitemid 37268213)
-
(2003)
Current Opinion in Pulmonary Medicine
, vol.9
, Issue.6
, pp. 492-497
-
-
Rosenfeld, M.1
Ramsey, B.W.2
Gibson, R.L.3
-
6
-
-
0036320272
-
Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis
-
DOI 10.1002/ppul.10127
-
J Emerson, M Rosenfeld, S McNamara, B Ramsey, RL Gibson Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis Pediatr Pulmonol 34 2002 91 100 (Pubitemid 34809519)
-
(2002)
Pediatric Pulmonology
, vol.34
, Issue.2
, pp. 91-100
-
-
Emerson, J.1
Rosenfeld, M.2
McNamara, S.3
Ramsey, B.4
Gibson, R.L.5
-
7
-
-
0029177535
-
Effects of Pseudomonas aeruginosa colonization on lung function and anthropometric variables in children with cystic fibrosis
-
A Pamukcu, A Bush, R Buchdahl Effects of Pseudomonas aeruginosa colonization on lung function and anthropometric variables in children with cystic fibrosis Pediatr Pulmonol 19 1995 10 15
-
(1995)
Pediatr Pulmonol
, vol.19
, pp. 10-15
-
-
Pamukcu, A.1
Bush, A.2
Buchdahl, R.3
-
8
-
-
0035002870
-
Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis
-
DOI 10.1067/mpd.2001.112897
-
GM Nixon, DS Armstrong, R Carzino et al. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis J Pediatr 138 2001 699 704 (Pubitemid 32417671)
-
(2001)
Journal of Pediatrics
, vol.138
, Issue.5
, pp. 699-704
-
-
Nixon, G.M.1
Armstrong, D.S.2
Carzino, R.3
Carlin, J.B.4
Olinsky, A.5
Robertson, C.F.6
Grimwood, K.7
-
9
-
-
0026831341
-
Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis
-
RL Henry, CM Mellis, L Petrovic Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis Pediatr Pulmonol 12 1992 158 161
-
(1992)
Pediatr Pulmonol
, vol.12
, pp. 158-161
-
-
Henry, R.L.1
Mellis, C.M.2
Petrovic, L.3
-
10
-
-
0031661390
-
1 and treatment intensity during Pseudomonas aeruginosa colonisation in patients with cystic fibrosis
-
1 and treatment intensity during Pseudomonas aeruginosa colonisation in patients with cystic fibrosis Thorax 53 1998 732 737 (Pubitemid 28408712)
-
(1998)
Thorax
, vol.53
, Issue.9
, pp. 732-737
-
-
Ballmann, M.1
Rabsch, P.2
Von Der Hardt, H.3
-
11
-
-
0034785481
-
Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition
-
DOI 10.1002/ppul.1120
-
MR Kosorok, L Zeng, SE West et al. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition Pediatr Pulmonol 32 2001 277 287 (Pubitemid 32938876)
-
(2001)
Pediatric Pulmonology
, vol.32
, Issue.4
, pp. 277-287
-
-
Kosorok, M.R.1
Zeng, L.2
West, S.E.H.3
Rock, M.J.4
Splaingard, M.L.5
Laxova, A.6
Green, C.G.7
Collins, J.8
Farrell, P.M.9
-
12
-
-
66849126372
-
Bugs, biofilms, and resistance in cystic fibrosis
-
JC Davies Bugs, biofilms, and resistance in cystic fibrosis Respir Care 54 2009 628 638
-
(2009)
Respir Care
, vol.54
, pp. 628-638
-
-
Davies, J.C.1
-
14
-
-
77953635880
-
Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis
-
EC Dasenbrook, W Checkley, CA Merlo, MW Konstan, N Lechtzin, MP Boyle Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis JAMA 303 2010 2386 2392
-
(2010)
JAMA
, vol.303
, pp. 2386-2392
-
-
Dasenbrook, E.C.1
Checkley, W.2
Merlo, C.A.3
Konstan, M.W.4
Lechtzin, N.5
Boyle, M.P.6
-
15
-
-
67249099362
-
Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients
-
T Bjarnsholt, PO Jensen, MJ Fiandaca et al. Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients Pediatr Pulmonol 44 2009 547 558
-
(2009)
Pediatr Pulmonol
, vol.44
, pp. 547-558
-
-
Bjarnsholt, T.1
Jensen, P.O.2
Fiandaca, M.J.3
-
16
-
-
77950914953
-
Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: The ELITE trial
-
F Ratjen, A Munck, P Kho, G Angyalosi Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial Thorax 65 2010 286 291
-
(2010)
Thorax
, vol.65
, pp. 286-291
-
-
Ratjen, F.1
Munck, A.2
Kho, P.3
Angyalosi, G.4
-
17
-
-
59649123905
-
Acquisition and eradication of P. aeruginosa in young children with cystic fibrosis
-
TA Douglas, S Brennan, S Gard et al. Acquisition and eradication of P. aeruginosa in young children with cystic fibrosis Eur Respir J 33 2009 305 311
-
(2009)
Eur Respir J
, vol.33
, pp. 305-311
-
-
Douglas, T.A.1
Brennan, S.2
Gard, S.3
-
18
-
-
50849131275
-
Shifting patterns of inhaled antibiotic use in cystic fibrosis
-
SM Moskowitz, SJ Silva, N Mayer-Hamblett et al. Shifting patterns of inhaled antibiotic use in cystic fibrosis Pediatr Pulmonol 43 2008 874 881
-
(2008)
Pediatr Pulmonol
, vol.43
, pp. 874-881
-
-
Moskowitz, S.M.1
Silva, S.J.2
Mayer-Hamblett, N.3
-
19
-
-
79953284775
-
Inhaled antibiotics for long-term therapy in cystic fibrosis
-
G Ryan, M Singh, K Dwan Inhaled antibiotics for long-term therapy in cystic fibrosis Cochrane Database Syst Rev 2011 CD001021
-
(2011)
Cochrane Database Syst Rev
, pp. 001021
-
-
Ryan, G.1
Singh, M.2
Dwan, K.3
-
20
-
-
0002101312
-
Celiac syndrome; Chemotherapy in infections of the respiratory tract associated with cystic fibrosis of the pancreas; Observations with penicillin and drugs of the sulfonamide group, with special reference to penicillin aerosol
-
PEA di Sant' Agnese, DH Andersen Celiac syndrome; chemotherapy in infections of the respiratory tract associated with cystic fibrosis of the pancreas; observations with penicillin and drugs of the sulfonamide group, with special reference to penicillin aerosol Am J Dis Child 72 1946 17 61
-
(1946)
Am J Dis Child
, vol.72
, pp. 17-61
-
-
Di Sant'Agnese, P.E.A.1
Andersen, D.H.2
-
21
-
-
13244279718
-
Nebulized antibiotic therapy: The evidence
-
DOI 10.1191/1479972305cd045rs
-
SP Conway Nebulized antibiotic therapy: the evidence Chronic Respir Dis 2 2005 35 41 (Pubitemid 40193822)
-
(2005)
Chronic Respiratory Disease
, vol.2
, Issue.1
, pp. 35-41
-
-
Conway, S.P.1
-
22
-
-
0022353251
-
Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum
-
PM Mendelman, AL Smith, J Levy, A Weber, B Ramsey, RL Davis Aminoglycoside penetration, inactivation, and efficiency in cystic fibrosis sputum Am Rev Respir Dis 132 1985 761 765 (Pubitemid 16247735)
-
(1985)
American Review of Respiratory Disease
, vol.132
, Issue.4
, pp. 761-765
-
-
Mendelman, P.M.1
Smith, A.L.2
Levy, J.3
-
23
-
-
0028432864
-
Nebulizer delivery of tobramycin to the lower respiratory tract
-
A Weber, A Smith, J Williams-Warren, B Ramsey, A Smith Nebulizer delivery of tobramycin to the lower respiratory tract Pediatr Pulmonol 17 1994 331 339
-
(1994)
Pediatr Pulmonol
, vol.17
, pp. 331-339
-
-
Weber, A.1
Smith, A.2
Williams-Warren, J.3
Ramsey, B.4
Smith, A.5
-
24
-
-
0024790626
-
Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis
-
AL Smith, BW Ramsey, DL Hedges et al. Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis Pediatr Pulmonol 7 1989 265 271
-
(1989)
Pediatr Pulmonol
, vol.7
, pp. 265-271
-
-
Smith, A.L.1
Ramsey, B.W.2
Hedges, D.L.3
-
25
-
-
0027287651
-
Efficacy of aerosolized tobramycin in patients with cystic fibrosis
-
DOI 10.1056/NEJM199306173282403
-
BW Ramsey, HL Dorkin, JD Eisenberg et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis N Engl J Med 328 1993 1740 1746 (Pubitemid 23170123)
-
(1993)
New England Journal of Medicine
, vol.328
, Issue.24
, pp. 1740-1746
-
-
Ramsey, B.W.1
Dorkin, H.L.2
Eisenberg, J.D.3
Gibson, R.L.4
Harwood, I.R.5
Kravitz, R.M.6
Schidlow, D.V.7
Wilmott, R.W.8
Astley, S.J.9
McBurnie, M.A.10
Wentz, K.11
Smith, A.L.12
-
26
-
-
0030898932
-
Effect of nebulizer type and antibiotic concentration on device performance
-
DOI 10.1002/(SICI)1099-0496(199704)23:4<249::AID-PPUL2>3.0.CO;2-H
-
A Weber, G Morlin, M Cohen, J Williams-Warren, B Ramsey, A Smith Effect of nebulizer type and antibiotic concentration on device performance Pediatr Pulmonol 23 1997 249 260 (Pubitemid 27185033)
-
(1997)
Pediatric Pulmonology
, vol.23
, Issue.4
, pp. 249-260
-
-
Weber, A.1
Morlin, G.2
Cohen, M.3
Williams-Warren, J.4
Ramsey, B.5
Smith, A.6
-
27
-
-
0036304163
-
Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis
-
DOI 10.1378/chest.122.1.219
-
DE Geller, WH Pitlick, PA Nardella, WG Tracewell, BW Ramsey Pharmacokinetics and bioavailability of aerosolized tobramycin (TOBI®) in cystic fibrosis Chest 122 2002 219 226 (Pubitemid 34754166)
-
(2002)
Chest
, vol.122
, Issue.1
, pp. 219-226
-
-
Geller, D.E.1
Pitlick, W.H.2
Nardella, P.A.3
Tracewell, W.G.4
Ramsey, B.W.5
-
28
-
-
0030999183
-
A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems
-
J Eisenberg, M Pepe, J Williams-Warren et al. A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems Chest 111 1997 955 962 (Pubitemid 27171467)
-
(1997)
Chest
, vol.111
, Issue.4
, pp. 955-962
-
-
Eisenberg, J.1
Pepe, M.2
Williams-Warren, J.3
Vasiliev, M.4
Bruce Montgomery, A.5
Smith, A.L.6
Ramsey, B.W.7
-
29
-
-
84873076258
-
-
Novartis Pharmaceuticals Corporation East Hanover, NJ (accessed October 3, 2011).
-
TOBI® (tobramycin inhalation solution) Prescribing Information 2009 Novartis Pharmaceuticals Corporation East Hanover, NJ Available at: www.pharma.us.novartis.com/product/pi/pdf/tobi.pdf (accessed October 3, 2011).
-
(2009)
TOBI® (Tobramycin Inhalation Solution) Prescribing Information
-
-
-
30
-
-
0033531143
-
Intermittent administration of inhaled tobramycin in patients with cystic fibrosis
-
DOI 10.1056/NEJM199901073400104
-
BW Ramsey, MS Pepe, JM Quan et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group N Engl J Med 340 1999 23 30 (Pubitemid 29024680)
-
(1999)
New England Journal of Medicine
, vol.340
, Issue.1
, pp. 23-30
-
-
Ramsey, B.W.1
Pepe, M.S.2
Quan, J.M.3
Otto, K.L.4
Montgomery, A.B.5
Williams-Warren, J.6
Vasiljev-K, M.7
Borowitz, D.8
Bowman, C.M.9
Marshall, B.C.10
Marshall, S.11
Smith, A.L.12
-
31
-
-
0036157901
-
Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis
-
DOI 10.1378/chest.121.1.55
-
RB Moss Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis Chest 121 2002 55 63 (Pubitemid 34114228)
-
(2002)
Chest
, vol.121
, Issue.1
, pp. 55-63
-
-
Moss, R.B.1
-
32
-
-
0034834836
-
Administration of aerosolized antibiotics in cystic fibrosis patients
-
RB Moss Administration of aerosolized antibiotics in cystic fibrosis patients Chest 120 3 Suppl 2001 107S 113S (Pubitemid 32881572)
-
(2001)
Chest
, vol.120
, Issue.SUPPL.
-
-
Moss, R.B.1
-
33
-
-
4544269731
-
Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease
-
DOI 10.1002/ppul.20097
-
TD Murphy, RD Anbar, LA Lester et al. Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease Pediatr Pulmonol 38 2004 314 320 (Pubitemid 39245114)
-
(2004)
Pediatric Pulmonology
, vol.38
, Issue.4
, pp. 314-320
-
-
Murphy, T.D.1
Anbar, R.D.2
Lester, L.A.3
Nasr, S.Z.4
Nickerson, B.5
VanDevanter, D.R.6
Colin, A.A.7
-
34
-
-
84855266619
-
Technological and behavioral strategies to reduce treatment burden and improve adherence to inhaled antibiotics in cystic fibrosis
-
DE Geller, S Madge Technological and behavioral strategies to reduce treatment burden and improve adherence to inhaled antibiotics in cystic fibrosis Respir Med 105 Suppl 2 2011 S24 S31
-
(2011)
Respir Med
, vol.105
, Issue.SUPPL. 2
-
-
Geller, D.E.1
Madge, S.2
-
35
-
-
34249945743
-
A formulation of aerosolized tobramycin (Bramitob®) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: A double-blind, placebo-controlled, multicenter study
-
DOI 10.2165/00148581-200709001-00004
-
A Chuchalin, E Csiszér, K Gyurkovics et al. A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study Paediatr Drugs 9 Suppl 1 2007 21 31 (Pubitemid 46879111)
-
(2007)
Pediatric Drugs
, vol.9
, Issue.SUPPL. 1
, pp. 21-31
-
-
Chuchalin, A.1
Csiszer, E.2
Gyurkovics, K.3
Bartnicka, M.T.4
Sands, D.5
Kapranov, N.6
Varoli, G.7
Preti, P.A.M.8
Mazurek, H.9
-
36
-
-
36248953255
-
Cystic fibrosis pulmonary guidelines: Chronic medications for maintenance of lung health
-
DOI 10.1164/rccm.200705-664OC
-
PA Flume, BP O'Sullivan, KA Robinson et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health Am J Respir Crit Care Med 176 2007 957 969 (Pubitemid 350127838)
-
(2007)
American Journal of Respiratory and Critical Care Medicine
, vol.176
, Issue.10
, pp. 957-969
-
-
Flume, P.A.1
O'Sullivan, B.P.2
Robinson, K.A.3
Goss, C.H.4
Mogayzel Jr., P.J.5
Willey-Courand, D.B.6
Bujan, J.7
Finder, J.8
Lester, M.9
Quittell, L.10
Rosenblatt, R.11
Vender, R.L.12
Hazle, L.13
Sabadosa, K.14
Marshall, B.15
-
37
-
-
77956566583
-
-
Gilead Sciences, Inc. Foster City, CA (accessed October 29, 2011).
-
Cayston® (aztreonam for inhalation solution). Prescribing Information 2010 Gilead Sciences, Inc. Foster City, CA Available at: https://www.cayston. com/assets/media/pdfs/CAYSTON-full-prescribing-information.pdf (accessed October 29, 2011).
-
(2010)
Cayston® (Aztreonam for Inhalation Solution). Prescribing Information
-
-
-
38
-
-
84873066911
-
-
accessed October 29, 2011
-
European Medicines Agency Cayston Available at: http://www.ema.europa.eu/ ema/index.jsp?curl=pages/medicines/human/medicines/000996/human-med-000686. jsp&mid=WC0b01ac058001d124 (accessed October 29, 2011).
-
Cayston
-
-
Medicines Agency, E.1
-
39
-
-
33745686502
-
Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis
-
RL Gibson, GZ Retch-Bogart, C Oermann et al. Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis Pediatr Pulmonol 41 2006 656 665
-
(2006)
Pediatr Pulmonol
, vol.41
, pp. 656-665
-
-
Gibson, R.L.1
Retch-Bogart, G.Z.2
Oermann, C.3
-
40
-
-
38349058630
-
A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection
-
GZ Retsch-Bogart, JL Burns, KL Otto et al. A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection Pediatr Pulmonol 43 2008 47 58
-
(2008)
Pediatr Pulmonol
, vol.43
, pp. 47-58
-
-
Retsch-Bogart, G.Z.1
Burns, J.L.2
Otto, K.L.3
-
41
-
-
65949124667
-
Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis
-
GZ Retsch-Bogart, AL Quittner, RL Gibson et al. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis Chest 135 2009 1223 1232
-
(2009)
Chest
, vol.135
, pp. 1223-1232
-
-
Retsch-Bogart, G.Z.1
Quittner, A.L.2
Gibson, R.L.3
-
42
-
-
55549137086
-
Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis
-
K McCoy, AL Quittner, CM Oermann, RL Gibson, GZ Retsch-Bogart, AB Montgomery Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis Am J Respir Crit Care Med 178 2008 921 928
-
(2008)
Am J Respir Crit Care Med
, vol.178
, pp. 921-928
-
-
McCoy, K.1
Quittner, A.L.2
Oermann, C.M.3
Gibson, R.L.4
Retsch-Bogart, G.Z.5
Montgomery, A.B.6
-
43
-
-
78449294500
-
An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis
-
CM Oermann, GZ Retsch-Bogart, AL Quittner et al. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis Pediatr Pulmonol 45 2010 1121 1134
-
(2010)
Pediatr Pulmonol
, vol.45
, pp. 1121-1134
-
-
Oermann, C.M.1
Retsch-Bogart, G.Z.2
Quittner, A.L.3
-
44
-
-
80052892852
-
Pseudomonas aeruginosa antibiotic susceptibility during long-term use of aztreonam for inhalation solution (AZLI)
-
CM Oermann, KS McCoy, GZ Retsch-Bogart, RL Gibson, M McKevitt, AB Montgomery Pseudomonas aeruginosa antibiotic susceptibility during long-term use of aztreonam for inhalation solution (AZLI) J Antimicrob Chemother 66 2011 2398 2404
-
(2011)
J Antimicrob Chemother
, vol.66
, pp. 2398-2404
-
-
Oermann, C.M.1
McCoy, K.S.2
Retsch-Bogart, G.Z.3
Gibson, R.L.4
McKevitt, M.5
Montgomery, A.B.6
-
45
-
-
79958295843
-
Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa
-
CE Wainwright, AL Quittner, DE Geller et al. Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa J Cyst Fibros 10 2011 234 242
-
(2011)
J Cyst Fibros
, vol.10
, pp. 234-242
-
-
Wainwright, C.E.1
Quittner, A.L.2
Geller, D.E.3
-
46
-
-
55549102981
-
Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience
-
CR Hansen, T Pressler, N Høiby Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience J Cyst Fibros 7 2008 523 530
-
(2008)
J Cyst Fibros
, vol.7
, pp. 523-530
-
-
Hansen, C.R.1
Pressler, T.2
Høiby, N.3
-
47
-
-
0023265976
-
Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection
-
T Jensen, SS Pedersen, S Garne, C Heilmann, N Høiby, C Koch Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection J Antimicrob Chemother 19 1987 831 838 (Pubitemid 17092071)
-
(1987)
Journal of Antimicrobial Chemotherapy
, vol.19
, Issue.6
, pp. 831-838
-
-
Jensen, T.1
Pedersen, S.S.2
Garne, S.3
-
48
-
-
0036736583
-
A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis
-
ME Hodson, CG Gallagher, JR Govan A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis Eur Respir J 20 2002 658 664
-
(2002)
Eur Respir J
, vol.20
, pp. 658-664
-
-
Hodson, M.E.1
Gallagher, C.G.2
Govan, J.R.3
-
50
-
-
69549135253
-
Inhaled medication and inhalation devices for lung disease in patients with CF: A European consensus
-
H Heijerman, E Westerman, S Conway, D Touw, G Döring, consensus working group Inhaled medication and inhalation devices for lung disease in patients with CF: a European consensus J Cyst Fibros 8 2009 295 315
-
(2009)
J Cyst Fibros
, vol.8
, pp. 295-315
-
-
Heijerman, H.1
Westerman, E.2
Conway, S.3
Touw, D.4
Döring, G.5
Working Group, C.6
-
52
-
-
36548999921
-
Compounded colistimethate as possible cause of fatal acute respiratory distress syndrome
-
KS McCoy Compounded colistimethate as possible cause of fatal acute respiratory distress syndrome N Engl J Med 357 2008 2310 2311
-
(2008)
N Engl J Med
, vol.357
, pp. 2310-2311
-
-
McCoy, K.S.1
-
53
-
-
78651536177
-
Adherence with tobramycin inhaled solution and health care utilization
-
BA Briesacher, AL Quittner, L Saiman, P Sacco, H Fouayzi, LM Quittell Adherence with tobramycin inhaled solution and health care utilization BMC Pulm Med 11 2011 5
-
(2011)
BMC Pulm Med
, vol.11
, pp. 5
-
-
Briesacher, B.A.1
Quittner, A.L.2
Saiman, L.3
Sacco, P.4
Fouayzi, H.5
Quittell, L.M.6
-
54
-
-
84885072715
-
-
accessed October 29, 2011
-
European Medicines Agency Colobreathe Available at: http://www.ema. europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001225/smops/ Positive/human-smop-000270.jsp&mid=WC0b01ac058001d127&jsenabled=true (accessed October 29, 2011).
-
Colobreathe
-
-
Medicines Agency, E.1
-
55
-
-
79961039597
-
Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere(tm) technology
-
DE Geller, J Weers, S Heuerding Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere(tm) technology J Aerosol Med Pulm Drug Deliv 24 2011 175 182
-
(2011)
J Aerosol Med Pulm Drug Deliv
, vol.24
, pp. 175-182
-
-
Geller, D.E.1
Weers, J.2
Heuerding, S.3
-
56
-
-
34247193128
-
Novel tobramycin inhalation powder in cystic fibrosis subjects: Pharmacokinetics and safety
-
DOI 10.1002/ppul.20594
-
DE Geller, M Konstan, J Smith, S Noonberg, C Conrad A novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety Pediatr Pulmonol 42 2007 307 313 (Pubitemid 46608898)
-
(2007)
Pediatric Pulmonology
, vol.42
, Issue.4
, pp. 307-313
-
-
Geller, D.E.1
Konstan, M.W.2
Smith, J.3
Moonberg, S.B.4
Conrad, C.5
-
57
-
-
79951840468
-
Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: The EVOLVE trial
-
MW Konstan, DE Geller, P Minie, F Brockhaus, J Zhang, G Angyalosi Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial Pediatr Pulmonol 46 2011 230 238
-
(2011)
Pediatr Pulmonol
, vol.46
, pp. 230-238
-
-
Konstan, M.W.1
Geller, D.E.2
Minie, P.3
Brockhaus, F.4
Zhang, J.5
Angyalosi, G.6
-
58
-
-
78651412529
-
Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial
-
MW Konstan, PA Flume, M Kappler et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial J Cyst Fibros 10 2011 54 61
-
(2011)
J Cyst Fibros
, vol.10
, pp. 54-61
-
-
Konstan, M.W.1
Flume, P.A.2
Kappler, M.3
-
60
-
-
84873063990
-
-
Insmed Incorporated Monmouth Junction, NJ (accessed October 29, 2011).
-
Arikace® (inhaled liposomal amikacin) 2011 Insmed Incorporated Monmouth Junction, NJ Available at: http://www.insmed.com/arikace.phpp1 (accessed October 29, 2011).
-
(2011)
Arikace® (Inhaled Liposomal Amikacin)
-
-
-
61
-
-
41149105955
-
Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections
-
DOI 10.1093/jac/dkn059
-
P Meers, M Neville, V Malinin et al. Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections J Antimicrob Chemother 61 2008 859 868 (Pubitemid 351426071)
-
(2008)
Journal of Antimicrobial Chemotherapy
, vol.61
, Issue.4
, pp. 859-868
-
-
Meers, P.1
Neville, M.2
Malinin, V.3
Scotto, A.W.4
Sardaryan, G.5
Kurumunda, R.6
Mackinson, C.7
James, G.8
Fisher, S.9
Perkins, W.R.10
-
62
-
-
66949178892
-
A randomized, placebo-controlled study of nebulized liposomal amikacin (Arikace) in the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection
-
Abstract 102.
-
L Dupont, P Minic, S Fustik et al. A randomized, placebo-controlled study of nebulized liposomal amikacin (Arikace) in the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection J Cyst Fibros 7 Suppl 2 2008 S26 Abstract 102.
-
(2008)
J Cyst Fibros
, vol.7
, Issue.SUPPL. 2
, pp. 26
-
-
Dupont, L.1
Minic, P.2
Fustik, S.3
-
63
-
-
84873073687
-
A multi-cycle open-label study of nebulized liposomal amikacin (Arikace®) in the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection
-
Abstract 217.
-
P Minic, S Fustik, E Solyom et al. A multi-cycle open-label study of nebulized liposomal amikacin (Arikace®) in the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection J Cyst Fibros 10 Suppl 1 2011 S55 Abstract 217.
-
(2011)
J Cyst Fibros
, vol.10
, Issue.SUPPL. 1
, pp. 55
-
-
Minic, P.1
Fustik, S.2
Solyom, E.3
-
64
-
-
66949153801
-
Pharmacokinetics of ciprofloxacin PulmoSphere® inhalational powder
-
Abstract 103.
-
H Stass, S Baumann-Noss, H Delesen et al. Pharmacokinetics of ciprofloxacin PulmoSphere® inhalational powder J Cyst Fibros 7 Suppl 2 2008 S26 Abstract 103.
-
(2008)
J Cyst Fibros
, vol.7
, Issue.SUPPL. 2
, pp. 26
-
-
Stass, H.1
Baumann-Noss, S.2
Delesen, H.3
-
65
-
-
66949159248
-
The effect of once-a-day inhaled liposomal ciprofloxacin hydrochloride on sputum bacterial density in cystic fibrosis patients with chronic pulmonary P. aeruginosa colonization
-
Abstract 401.
-
P Bruinenberg, B Otulana, J Blanchard et al. The effect of once-a-day inhaled liposomal ciprofloxacin hydrochloride on sputum bacterial density in cystic fibrosis patients with chronic pulmonary P. aeruginosa colonization Pediatr Pulmonol 43 Suppl 31 2008 344 Abstract 401.
-
(2008)
Pediatr Pulmonol
, vol.43
, Issue.SUPPL. 31
, pp. 344
-
-
Bruinenberg, P.1
Otulana, B.2
Blanchard, J.3
-
66
-
-
73849128431
-
In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis
-
P King, O Lomovskaya, DC Griffith, JL Burns, MN Dudley In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis Antimicrob Agents Chemother 54 2010 143 148
-
(2010)
Antimicrob Agents Chemother
, vol.54
, pp. 143-148
-
-
King, P.1
Lomovskaya, O.2
Griffith, D.C.3
Burns, J.L.4
Dudley, M.N.5
-
67
-
-
73749084328
-
Effect of oxygen limitation on the in vitro activity of levofloxacin and other antibiotics administered by the aerosol route against Pseudomonas aeruginosa from cystic fibrosis patients
-
P King, DM Citron, DC Griffith, O Lomovskaya, MN Dudley Effect of oxygen limitation on the in vitro activity of levofloxacin and other antibiotics administered by the aerosol route against Pseudomonas aeruginosa from cystic fibrosis patients Diagn Microbiol Infect Dis 66 2010 181 186
-
(2010)
Diagn Microbiol Infect Dis
, vol.66
, pp. 181-186
-
-
King, P.1
Citron, D.M.2
Griffith, D.C.3
Lomovskaya, O.4
Dudley, M.N.5
-
68
-
-
79957942626
-
Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa
-
Mpex204 Study Group
-
DE Geller, PA Flume, D Staab, R Fischer, JS Loutit, DJ Conrad, Mpex204 Study Group Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa Am J Respir Crit Care Med 183 2011 1510 1516
-
(2011)
Am J Respir Crit Care Med
, vol.183
, pp. 1510-1516
-
-
Geller, D.E.1
Flume, P.A.2
Staab, D.3
Fischer, R.4
Loutit, J.S.5
Conrad, D.J.6
-
69
-
-
84855292491
-
Fosfomycin/tobramycin for inhalation in cystic fibrosis patients with Pseudomonas airway infection
-
in press
-
BC Trapnell, SA McColley, DG Kissner et al. Fosfomycin/tobramycin for inhalation in cystic fibrosis patients with Pseudomonas airway infection Am J Respir Crit Care Med 2011 (in press).
-
(2011)
Am J Respir Crit Care Med
-
-
Trapnell, B.C.1
McColley, S.A.2
Kissner, D.G.3
|